What is Kite Pharma?
Founded in 2009 and headquartered in Santa Monica, California, Kite Pharma is a pioneering pharmaceutical entity dedicated to the development of engineered T cell therapies. The company distinguishes itself from traditional drug manufacturers by focusing on personalized medicine, where a patient's own immune cells are modified to target and eliminate cancer cells. With specialized manufacturing facilities located in California, Maryland, and the Netherlands, Kite Pharma maintains a robust operational footprint that supports its global research and development efforts. The company's commitment to advancing cancer immunotherapy is evidenced by its focus on hematologic malignancies, aiming to provide curative options for patients with limited therapeutic alternatives.
How much funding has Kite Pharma raised?
Kite Pharma has raised a total of $225M across 4 funding rounds:
Private Equity
$12.5M
Series A
$35M
Debt
$50M
Stock Offering
$127.5M
Private Equity (2011): $12.5M, investors not publicly disclosed
Series A (2013): $35M led by Arie Belldegrun, Commercial Street Capital, Pontifax Ltd., Alta Partners, David Bonderman, and Michael Milken
Debt (2014): $50M, investors not publicly disclosed
Stock Issuance/Offering (2014): $127.5M, investors not publicly disclosed
Key Investors in Kite Pharma
Pontifax Ltd.
Pontifax Venture Capital specializes in groundbreaking innovations in life sciences, focusing on transformative healthcare technologies across all development stages.
Alta Partners
Alta Partners is a prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996.
Arie Belldegrun
Undisclosed investor participating in the funding round.
What's next for Kite Pharma?
Looking ahead, Kite Pharma is poised to leverage its recent capital influx to further optimize its cell therapy manufacturing processes and expand its clinical pipeline. The strategic deployment of these funds will likely focus on enhancing the scalability of its T cell engineering platform, ensuring that these innovative treatments reach a broader patient population. As the company continues to navigate the complex landscape of biotechnology, its focus remains on clinical excellence and the commercialization of its proprietary therapies. By maintaining strong relationships with its key investors and continuing to invest in research, Kite Pharma is well-positioned to sustain its growth trajectory and influence the future of oncology treatment paradigms.
See full Kite Pharma company page
